BidaskClub upgraded shares of Collegium Pharmaceutical (NASDAQ:COLL) from a hold rating to a buy rating in a research note issued to investors on Wednesday.
A number of other research firms have also recently issued reports on COLL. TheStreet upgraded shares of Collegium Pharmaceutical from a d+ rating to a c rating in a research note on Wednesday, March 7th. Piper Jaffray set a $33.00 target price on shares of Collegium Pharmaceutical and gave the stock a buy rating in a research note on Tuesday, January 23rd. HC Wainwright raised their target price on shares of Collegium Pharmaceutical from $21.00 to $33.00 and gave the stock a buy rating in a research note on Thursday, March 8th. William Blair restated an outperform rating on shares of Collegium Pharmaceutical in a research note on Thursday, March 8th. Finally, Zacks Investment Research cut shares of Collegium Pharmaceutical from a buy rating to a hold rating in a research note on Friday, February 2nd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the stock. The company currently has an average rating of Buy and a consensus target price of $29.17.
NASDAQ COLL opened at $25.55 on Wednesday. Collegium Pharmaceutical has a 52-week low of $7.37 and a 52-week high of $29.90.
In related news, Chairman Michael Thomas Heffernan sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, January 23rd. The shares were sold at an average price of $25.01, for a total transaction of $500,200.00. Following the transaction, the chairman now directly owns 535,395 shares of the company’s stock, valued at $13,390,228.95. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Alison B. Fleming sold 6,928 shares of the firm’s stock in a transaction dated Wednesday, January 10th. The stock was sold at an average price of $19.07, for a total transaction of $132,116.96. Following the transaction, the insider now directly owns 32,651 shares in the company, valued at $622,654.57. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 46,928 shares of company stock worth $1,082,317. 25.76% of the stock is owned by insiders.
A number of large investors have recently added to or reduced their stakes in COLL. Citadel Advisors LLC increased its position in Collegium Pharmaceutical by 773.8% during the third quarter. Citadel Advisors LLC now owns 544,033 shares of the specialty pharmaceutical company’s stock worth $5,707,000 after acquiring an additional 481,771 shares during the period. First Manhattan Co. bought a new position in Collegium Pharmaceutical during the fourth quarter worth about $8,606,000. Deutsche Bank AG increased its position in Collegium Pharmaceutical by 528.0% during the fourth quarter. Deutsche Bank AG now owns 414,115 shares of the specialty pharmaceutical company’s stock worth $7,643,000 after acquiring an additional 348,169 shares during the period. Cortina Asset Management LLC bought a new position in Collegium Pharmaceutical during the fourth quarter worth about $5,476,000. Finally, Macquarie Group Ltd. increased its position in Collegium Pharmaceutical by 21.5% during the fourth quarter. Macquarie Group Ltd. now owns 1,616,117 shares of the specialty pharmaceutical company’s stock worth $29,833,000 after acquiring an additional 286,138 shares during the period. 86.39% of the stock is currently owned by institutional investors and hedge funds.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving.
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.